Wei Li1, Ke-Jia Liu1, Jing-Song Song2, Rui Song1, Zi-Liang Liu1. 1. Department of Oncology, The First Peoples Hospital of Tianmen City Tianmen 431700, Hubei Province, China. 2. Department of Cardiothoracic Surgery, The First Peoples Hospital of Tianmen City Tianmen 431700, Hubei Province, China.
Abstract
BACKGROUND: RAD51 interacting with BRCA1 and BRCA2 could modulate the penetrance of BRCA1/BRCA2 mutations, which may increase susceptibility for breast cancer by inhibiting DNA repair and genome stability. The purpose of this study was to provide refined statistical evidence for the association between RAD51 polymorphism and breast cancer risk. DESIGN AND RESULTS: We conducted a meta-analysis of 15 publications with a total of 11,766 cancer cases and 11,227 controls. We summarized the data on the association of RAD51 polymorphism with breast cancer risk and performed subgroup analyses by ethnicity and control source. The pooled ORs based on fixed-effects model did not indicate a modified risk of breast cancer associated with RAD51 polymorphism in the overall population. Nor did we find a significant association in any stratified analysis. CONCLUSIONS: This meta-analysis suggested that RAD51 polymorphism did not appear to represent a significant risk factor for breast cancer.
BACKGROUND:RAD51 interacting with BRCA1 and BRCA2 could modulate the penetrance of BRCA1/BRCA2 mutations, which may increase susceptibility for breast cancer by inhibiting DNA repair and genome stability. The purpose of this study was to provide refined statistical evidence for the association between RAD51 polymorphism and breast cancer risk. DESIGN AND RESULTS: We conducted a meta-analysis of 15 publications with a total of 11,766 cancer cases and 11,227 controls. We summarized the data on the association of RAD51 polymorphism with breast cancer risk and performed subgroup analyses by ethnicity and control source. The pooled ORs based on fixed-effects model did not indicate a modified risk of breast cancer associated with RAD51 polymorphism in the overall population. Nor did we find a significant association in any stratified analysis. CONCLUSIONS: This meta-analysis suggested that RAD51 polymorphism did not appear to represent a significant risk factor for breast cancer.
Entities:
Keywords:
RAD51; breast cancer; polymorphism; susceptibility
Authors: Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei Journal: Mutat Res Date: 2002-11-30 Impact factor: 2.433
Authors: Haiming Sun; Jing Bai; Feng Chen; Yan Jin; Yang Yu; Lianhong Jin; Songbin Fu Journal: Breast Cancer Res Treat Date: 2010-05-08 Impact factor: 4.872
Authors: Lin-Bo Gao; Xin-Min Pan; Li-Juan Li; Wei-Bo Liang; Yi Zhu; Lu-Shun Zhang; Yong-Gang Wei; Ming Tang; Lin Zhang Journal: Breast Cancer Res Treat Date: 2010-07-17 Impact factor: 4.872
Authors: Jennifer Brooks; Roy E Shore; Anne Zeleniuch-Jacquotte; Diane Currie; Yelena Afanasyeva; Karen L Koenig; Alan A Arslan; Paolo Toniolo; Isaac Wirgin Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Paul D P Pharoah; Jonathan Tyrer; Alison M Dunning; Douglas F Easton; Bruce A J Ponder Journal: PLoS Genet Date: 2007-02-02 Impact factor: 5.917
Authors: L Kadouri; Z Kote-Jarai; A Hubert; F Durocher; D Abeliovich; B Glaser; T Hamburger; R A Eeles; T Peretz Journal: Br J Cancer Date: 2004-05-17 Impact factor: 7.640